TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TransCode Therapeutics to post earnings of ($3.21) per share and revenue of $0.30 million for the quarter.
TransCode Therapeutics Stock Down 0.9 %
NASDAQ RNAZ opened at $0.46 on Friday. The firm’s fifty day simple moving average is $4.60 and its two-hundred day simple moving average is $207.29. TransCode Therapeutics has a 12-month low of $0.38 and a 12-month high of $66.33.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TransCode Therapeutics in a research report on Thursday, March 13th.
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- Profitably Trade Stocks at 52-Week Highs
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Are Penny Stocks a Good Fit for Your Portfolio?
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- What Makes a Stock a Good Dividend Stock?
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
